Biotech Values

[ghmm]

Late-Stage Products Looking for a Home

Criteria for inclusion:
a) Program has completed phase-2b or later and is non-partnered; AND
b) Company lacks the financial resources to commercialize the product on its own.


Edits: Added HNAB-Marqibo (not a recommendation just to get this list going again.)

 
 Company   Product     Phase   Indication (notes) 
 =======   =======     =====   ================== 
 ARNA      Lorcaserin  NDA     Obesity 
 BPAX      Libigel     3       Female Sexual Desire Disorder 
 DDSS      Oleptro     apprvd  Depression (reformltn of generic trazodone) 
 HNAB      Marqibo     3       ALL (ENZN failed accelerated approval in NHL) 
 JAV       Dyloject    NDA     Post-op pain (approved in UK) 
 JAV       Ketamine    3       Acute pain 
 OREX      Contrave    NDA     Obesity 
 OXGN      Zybrestat   3       Anaplastic thyroid cancer 
 MNKD      Afrezza     BLA     Diabetes (CRL rec’d 3/15/10) 
 Pharming  Rhucin      BLA     HAE (rejected and resubmitted in EU) 
 SOMX      Silenor     apprvd  Insomnia (low dose of generic doxepin) 
 SVNT      Krystexxa   BLA     Gout (response to CRL submitted 3/30/10) 
 VVUS      Qnexa       NDA     Obesity 
  
 

Procedure for Updating Table

1. Copy the text in this post into a word processor.

2. Using a monospace font (e.g. Courier) to facilitate tabular
alignment, make your additions and modifications, inserting
them in the table in alphabetical order. NOTE: use spaces
rather than tab characters.

3. Add a brief note in the “Edits:” line atop the table to
describe your changes.

4. Insert the iHub formatting directives: Put [ pre ] at the
beginning of the table without the surrounding spaces, and
put [ /pre ] at the end of the table without the surrounding
spaces.

5. Post your text as a reply to this message.

Thank you for your cooperation.